Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease

Movement Disorders

Volumn 27, Issue 8, 2012, Pages 1004-1011

  Elliott, David A ^a,b   Kim, Woojin S ^a,b   Gorissen, Sarsha ^a   Halliday, Glenda M ^a,b   Kwok, John B J ^a,b  

^a NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alpha synuclein; Alternative splicing; Dystonin; Leucine rich repeat kinase 2; Microarray; Microtubule associated protein tau.; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; BULLOUS PEMPHIGOID ANTIGEN 1; DNA BINDING PROTEIN; LEUCINE RICH REPEAT KINASE 2; RNA; TAU PROTEIN;

AGED; ALTERNATIVE RNA SPLICING; ARTICLE; AUTOPSY; BRAIN TISSUE; CELL CYCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; EXON; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROTUBULE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROPATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA METABOLISM; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALTERNATIVE SPLICING; AUTOPSY; DNA, COMPLEMENTARY; DNA-BINDING PROTEINS; EXONS; FEMALE; GENE DOSAGE; GENE EXPRESSION; HUMANS; MALE; MEMBRANE MICRODOMAINS; MUTATION; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; REAL-TIME POLYMERASE CHAIN REACTION; TAU PROTEINS;

EID: 84864019604     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25005     Document Type: Article

References (33)

1. Bertram L, Tanzi RE. The genetic epidemiology of neurodegenerative disease. J Clin Invest 2005; 115: 1449-1457.
2. Arima K, Uéda K, Sunohara N, et al. Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 1998; 808: 93-100.
3. Marín I, van Egmond WN, van Haastert PJ. The Roco protein family: a functional perspective. FASEB J 2008; 22: 3103-3110.
4. Dihanich S, Manzoni C. LRRK2: a problem lurking in vesicle trafficking? J Neurosci 2011; 31: 9787-9788.
5. Hatano T, Kubo S, Imai S, et al. Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 2007; 16: 678-690.
6. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010; 466: 637-641.
7. Cookson MR. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci 2010; 11: 791-797.
8. Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C. Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. Parkinsonism Relat Disord 2010; 16: 237-242.
9. Wider C, Dickson DW, Wszolek ZK. Leucine-rich repeat kinase 2 gene-associated disease: redefining genotype-phenotype correlation. Neurodegener Dis 2010; 7: 175-179.
10. Berwick DC, Harvey K. LRRK2 signaling pathways: the key to unlocking neurodegeneration? Trends Cell Biol 2011; 2: 257-265.
11. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336.
12. Lagier-Tourenne C, Polymenidou M, Cleveland DW. TDP-43 and FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum Mol Genet 2010; 19: R46-R64.
13. Maracchioni A, Totaro A, Angelini DF, et al. Mitochondrial damage modulates alternative splicing in neuronal cells: implications for neurodegeneration. J Neurochem 2007; 100: 142-153.
14. Qing H, Wong W, McGeer EG, McGeer PL. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun 2009; 387: 149-152.
15. Sreedharan J, Blair IP, Tripathi VB, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 2008; 319: 1668-1672.
16. Vance C, Rogelj B, Hortobágyi T, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009; 323: 1208-1211.
17. Luty AA, Kwok JB, Dobson-Stone C, et al. Sigma nonopioid intracellular receptor 1 mutations cause frontotemporal lobar degeneration-motor neuron disease. Ann Neurol 2010; 68: 639-649.
18. Adam RM, Yang W, Di Vizio D, Mukhopadhyay NK, Steen H. Rapid preparation of nuclei-depleted detergent-resistant membrane fractions suitable for proteomics analysis. BMC Cell Biol 2008; 9: 30.
19. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Statist Soc Ser B 1995; 57: 289-300.
20. Antonov AV. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic Acids Res 2011; 39 (Web Server issue):W323-W327.
21. Urwin H, Ghazi-Noori S, Collinge J, Isaacs A. The role of CHMP2B in frontotemporal dementia. Biochem Soc Trans 2009; 37: 208-212.
22. Perron MP, Provost P. Protein components of the microRNA pathway and human diseases. Methods Mol Biol 2009; 487: 369-385.
23. Liu B, Liu Y, Chen J, et al. CARP is a novel caspase recruitment domain containing pro-apoptotic protein. Biochem Biophys Res Commun 2002; 293: 1396-1404.
24. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010; 74: 97-109.
25. Lee H, Dean C, Isacoff E. Alternative splicing of neuroligin regulates the rate of presynaptic differentiation. J Neurosci 2010; 30: 11435-11446.
26. Iliescu A, Gravel M, Horth C, Kibar Z, Gros P. Loss of membrane targeting of Vangl proteins causes neural tube defects. Biochemistry 2011; 50: 795-804.
27. Kicka S, Shen Z, Annesley SJ, Fisher PR, Lee S, Briggs S, Firtel RA. The LRRK2-related Roco kinase Roco2 is regulated by Rab1A and controls the actin cytoskeleton. Mol Biol Cell 2011; 22: 2198-2211.
28. Sonnenberg A, Liem RK. Plakins in development and disease. Exp Cell Res 2007; 313: 2189-2203.
29. Leung CL, Zheng M, Prater SM, Liem RK. The BPAG1 locus: alternative splicing produces multiple isoforms with distinct cytoskeletal linker domains, including predominant isoforms in neurons and muscles. J Cell Biol 2001; 154: 691-697.
30. D'Souza I, Schellenberg GD. Regulation of tau isoform expression and dementia. Biochim Biophys Acta 2005; 1739: 104-115.
31. Beyer K. Alpha-synuclein structure, posttranslational modification, and alternative splicing as aggregation enhancers. Acta Neuropathol 2006; 112: 237-251.
32. Kwok JB, Teber ET, Loy C et al. Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 2004; 55: 329-334.
33. Polymenidou M, Lagier-Tourenne C, Hutt KR, et al. Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43. Nat Neurosci 2011; 14: 459-468.